There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

Identifying individuals with hereditary syndromes allows for improved cancer surveillance, risk reduction, and optimized management. Establishing criteria for assessment allows for the identification of individuals who are carriers of pathogenic genetic variants.

Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.

The approval of new therapies has substantially expanded the treatment options for metastatic colorectal cancer (mCRC) in recent years, raising new questions about how to select the most appropriate therapy for a specific patient and how to optimally sequence these therapies.

Each of the therapies for mCRC are associated with certain toxicities, many of which differ depending on the mechanism of action; therefore, the supportive care needs of patients receiving systemic therapy for mCRC vary.

The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well as recommended screening strategies for individuals at average or increased-risk of developing sporadic CRC.

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.